Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vericel's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vericel's regulatory disclosures and financial reporting.
Vericel Corporation reports a strong 2025 and asks shareholders to vote on key governance items at its virtual annual meeting on April 29, 2026. Total net revenue reached $276.3 million, with MACI contributing $239.5 million, up 21% and marking a third straight year of 20%+ growth.
Gross margin improved to 74%, non-GAAP adjusted EBITDA was $70.9 million (up 33%), and GAAP net income was $16.5 million, a 59% increase and the second consecutive profitable year. The company ended 2025 with nearly $200 million in cash and investments and no debt.
Growth was driven by MACI and the arthroscopic MACI Arthro technique, expansion of the sales force, and a burn care franchise that generated $36.8 million in revenue. Vericel initiated the MACI Ankle MASCOT phase 3 study and secured FDA approval for commercial MACI manufacturing at its new advanced facility, supporting a planned MACI launch in the United Kingdom in 2027.
Shareholders are being asked to elect seven directors, approve on an advisory basis executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for 2026. The proxy also highlights robust governance practices, director pay structure, and stock ownership guidelines.
Vericel Corp’s Chief Legal Officer Sean C. Flynn exercised options for 15,000 shares and sold a total of 21,421 common shares of VCEL on March 2, 2026. The sales, executed at prices around $34.75 and $35.36, were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. Following these transactions, Flynn directly held 1,262 common shares and 85,000 option-based rights.
Vericel Corp's Chief Operating Officer, Michael Halpin, sold 10,305 shares of common stock in an open-market transaction at $35.30 per share on March 2, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan he adopted on December 2, 2025, leaving him with 16,080 directly owned shares.
Vericel Corporation filed a Form 144 reporting an affiliate sale of common stock; the filing lists a 03/02/2026 proposed sale tied to an option exercise of 15,000 shares through Fidelity Brokerage Services LLC. The filing also lists recent restricted stock vesting entries of 1,510, 1,295, 1,947, and 1,669 shares on 02/17/2026, 02/18/2026, 02/20/2026, and 02/22/2026, respectively.
VCEL submitted a Form 144 reporting planned sales of common stock held at Fidelity Brokerage Services LLC. The notice lists multiple restricted stock vesting entries: 2,764 shares on 02/17/2026, 2,013 shares on 02/18/2026, 2,764 shares on 02/20/2026, and 2,764 shares on 02/22/2026.
The filing identifies the broker as Fidelity Brokerage Services LLC and indicates Nasdaq as the market; additional transactional details are not included in the excerpt.
Vericel Corp President and CEO Dominick Colangelo reported equity award vesting and related share movements. On February 24, 2026, he acquired a total of 36,500 shares of common stock through the exercise or conversion of restricted stock units, with a portion converted into phantom stock units and deferred under Vericel’s Deferred Compensation Plan. The company withheld 8,824 shares of common stock at a fair market value of $38.09 per share to cover tax obligations tied to the vesting. After these transactions, Colangelo directly owned 312,446 shares of Vericel common stock.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported multiple equity compensation transactions tied to restricted stock units (RSUs). On the transaction date, several RSU awards vested and were converted to common stock, and some RSUs were deferred into phantom stock under Vericel’s Deferred Compensation Plan. The company withheld 1,335 and 636 shares of common stock to satisfy tax obligations at fair market values of $38.09 and $38.25 per share. Following these transactions, Hopper directly owned 75,556 shares of Vericel common stock.
Vericel Corporation’s Principal Accounting Officer, Jonathan Siegal, reported equity award activity involving restricted stock units (RSUs) and common stock. On February 24, 2026, he acquired 1,540 and 1,875 shares of common stock upon vesting of previously granted RSUs.
To cover tax obligations from these vestings, 627 and 738 shares of common stock were withheld by the company at fair market values of $38.09 and $38.25 per share. Following these transactions, Siegal directly owned 5,847 shares of Vericel common stock, along with remaining unvested RSUs scheduled to vest in future years.
Vericel Corp’s Chief Financial Officer Mara Joseph Anthony Jr reported equity compensation activity rather than open-market trading. On February 24, 2026, restricted stock units vested and were converted into common stock, with blocks of 4,625 shares each delivered. In connection with these vestings, 1,358 shares were withheld in two separate transactions at fair market values of $38.09 and $38.25 per share to cover tax obligations. Following these transactions, Anthony continued to hold common stock directly.